Long-term auditory complications after childhood cancer: A report from the Swiss Childhood Cancer Survivor Study.

Weiss, Annette; Sommer, Grit; Kasteler, Rahel; Scheinemann, Katrin; Grotzer, Michael; Kompis, Martin; Kuehni, Claudia E (2017). Long-term auditory complications after childhood cancer: A report from the Swiss Childhood Cancer Survivor Study. Pediatric blood & cancer, 64(2), pp. 364-373. Wiley-Liss 10.1002/pbc.26212

[img] Text
Weiss PediatrBloodCancer 2017.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (564kB)
[img]
Preview
Text
Weiss PediatrBloodCancer 2017_postprint.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (566kB) | Preview

BACKGROUND

Auditory complications are an adverse event of childhood cancer treatment, especially common in children treated with platinum chemotherapy or cranial radiation. Variation between diagnostic childhood cancer groups has rarely been studied, and we do not know if the burden of auditory complications has changed over the last decades.

PROCEDURE

Within the Swiss Childhood Cancer Survivor Study, we sent a questionnaire to all survivors who were diagnosed at age 16 years or less between 1976 and 2005. We compared prevalence of self-reported hearing loss and tinnitus between all diagnostic childhood cancer groups and siblings, used multivariable logistic regression to analyze the effect of treatment-related factors on hearing loss, and compared the cumulative incidence of hearing loss between different periods of cancer diagnosis.

RESULTS

Prevalence of self-reported hearing loss was higher in survivors (10%) than in siblings (3%, P < 0.001), and highest in survivors of central nervous system tumors (25%). Significant risk factors were treatment with platinum compounds (carboplatin: odds ratio [OR] 2.4; cisplatin: OR 9.4), cranial radiation (>29 Gy: OR >1.7), or brain surgery (OR 2.2). Children diagnosed in 1986-1995, when platinum compounds came into widespread use, had a significantly higher cumulative incidence of hearing loss than those diagnosed in 1976-1985. In the most recent period, 1996-2005, the risk decreased again, both for patients treated with platinum compounds and with cranial radiation.

CONCLUSIONS

Our data show that the burden of hearing loss has stabilized in recently treated survivors, suggesting that survivors have benefited from new treatment regimens that use less ototoxic radiation and more carefully dosed platinum compounds.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ear, Nose and Throat Disorders (ENT)

Graduate School:

Graduate School for Cellular and Biomedical Sciences (GCB)
Graduate School for Health Sciences (GHS)

UniBE Contributor:

Weiss, Annette Gerda, Sommer, Grit, Kompis, Martin, Kühni, Claudia

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1545-5009

Publisher:

Wiley-Liss

Language:

English

Submitter:

Beatrice Minder Wyssmann

Date Deposited:

29 Sep 2016 11:42

Last Modified:

02 Mar 2023 23:28

Publisher DOI:

10.1002/pbc.26212

PubMed ID:

27650356

Uncontrolled Keywords:

Europe; cancer registry; childhood cancer survivors; cranial radiation; ototoxicity; platinum compounds

BORIS DOI:

10.7892/boris.89011

URI:

https://boris.unibe.ch/id/eprint/89011

Actions (login required)

Edit item Edit item
Provide Feedback